A Phase 1 Study of E7090 in Subjects With Solid Tumor

Trial Profile

A Phase 1 Study of E7090 in Subjects With Solid Tumor

Recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Oct 2017

At a glance

  • Drugs E 7090 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 26 Oct 2017 Results of dose-escalation part of this study (n=24; as of 28 Mar 2017) presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017
    • 31 Oct 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top